Replimune (REPL) Non-Current Assets (2018 - 2026)
Replimune (REPL) reported Non-Current Assets of $53.3 million for Q1 2026, down 3.93% on a YoY basis from $55.4 million in Q1 2025, and little changed sequentially from $53.2 million in Q4 2025.
Replimune (REPL) Non-Current Assets (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Non-Current Assets data on file, last reported at $53.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 3.93% year-over-year to $53.3 million; the trailing twelve-month figure through Mar 2026 stood at $218.3 million (down 1.52% YoY), and the FY2026 full-year result was $53.3 million, down 3.93% from the prior year.
- Non-Current Assets steadied at $53.3 million in Q1 2026, from $53.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $57.5 million in Q2 2022 to a low of $53.2 million in Q4 2025.
- A 5-year average of $55.1 million and a median of $54.6 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets decreased 6.32% in 2023 and rose 4.25% in 2024, its largest moves.
- Tracing REPL's Non-Current Assets over 5 years: stood at $54.6 million in 2022, then dropped by 1.51% to $53.8 million in 2023, then grew by 4.25% to $56.1 million in 2024, then declined by 5.02% to $53.2 million in 2025, then increased by 0.06% to $53.3 million in 2026.
- Business Quant data shows REPL's Non-Current Assets at $53.3 million in Q1 2026, $53.2 million in Q4 2025, and $55.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 53.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.27 Mn |
| Dec 31, 2025 | 53.24 Mn |
| Sep 30, 2025 | 55.70 Mn |
| Jun 30, 2025 | 56.14 Mn |
| Mar 31, 2025 | 55.45 Mn |
| Dec 31, 2024 | 56.05 Mn |
| Sep 30, 2024 | 55.57 Mn |
| Jun 30, 2024 | 54.65 Mn |
| Mar 31, 2024 | 54.06 Mn |
| Dec 31, 2023 | 53.77 Mn |
| Sep 30, 2023 | 54.22 Mn |
| Jun 30, 2023 | 53.85 Mn |
| Mar 31, 2023 | 53.99 Mn |
| Dec 31, 2022 | 54.59 Mn |
| Sep 30, 2022 | 56.71 Mn |
| Jun 30, 2022 | 57.48 Mn |
| Mar 31, 2022 | 57.22 Mn |
| Dec 31, 2021 | 57.49 Mn |
| Sep 30, 2021 | 59.08 Mn |
| Jun 30, 2021 | 59.16 Mn |